100 Recruiting Trials

Clinical Trials
for Breast Cancer in Connecticut

100 clinical trials for Breast Cancer are currently recruiting participants at study sites in Connecticut. Study-related care is provided at no cost.

100
Recruiting trials
120
Study sites
27
Cities
55
Industry-sponsored
36
Phase 2
27
Phase 3

Breast Cancer clinical trials in Connecticut: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In Connecticut, recruiting breast cancer studies are concentrated in New Haven, Hartford, Stamford and Trumbull, with sites in 23 other cities. 55 of the 100 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 100 recruiting Breast Cancer trials in Connecticut

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
PHASE3 Greenbrae, California +4 sites NCT05646862
This trial is looking for people with advanced breast cancer that has specific mutations and has not improved after certain treatments. Participants will compare two treatment combinations to see which is more effective and safe.
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
PHASE3 Daphne, Alabama +4 sites NCT06103864
This trial is looking for patients with a specific type of breast cancer that is not treatable by surgery. Participants will receive a treatment called Dato-DXd, with or without another drug, or a standard chemotherapy treatment.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3 Daphne, Alabama +4 sites NCT06492616
This trial is looking for women and men with early breast cancer that has a high risk of coming back. Participants will compare the effects of elacestrant with standard treatment after being on another therapy for a while.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
PHASE3 Phoenix, Arizona +4 sites NCT06072612
This trial is looking for adults with advanced or locally recurrent breast cancer who have run out of treatment options. Participants will receive treatment with the Bria-IMT regimen and a checkpoint inhibitor to see how well it works compared to other standard treatments.
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3 Phoenix, Arizona +4 sites NCT06748222
This trial is looking for younger women who have survived breast cancer and are experiencing depression. Participants will try two different mindfulness programs, one led by an instructor via Zoom and the other through a mobile app.
Recruiting
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
PHASE2 New Haven, Connecticut +4 sites NCT06533826
This trial is looking for women with advanced breast cancer that is HER2-negative. Participants will take part in a treatment involving two investigational drugs to see how effective they are.
Recruiting
ATEMPT 2.0: Adjuvant T-DM1 vs TH
PHASE2 Derby, Connecticut +4 sites NCT04893109
This trial is looking for patients with early-stage breast cancer that tests positive for HER2. Participants will receive one of two treatment options after surgery to see how well they work.
Recruiting
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
PHASE2 Stamford, Connecticut +4 sites NCT04468061
This trial is looking for adults with advanced triple-negative breast cancer that has spread and is PD-L1-negative. Participants will receive either sacituzumab govitecan or pembrolizumab, and may need to undergo biopsies during the trial.
Recruiting
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
PHASE1 New Haven, Connecticut NCT05989347
This trial is looking for women with early-stage HER2-negative breast cancer who are planning to receive chemotherapy. Participants will take a medication called dapagliflozin while undergoing treatment to help assess certain health markers.
Recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NA New Haven, Connecticut +4 sites NCT05890677
This trial is looking for people who have long-term lymphedema caused by breast cancer. Participants will compare the quality of life after surgery versus just conservative treatment about a year later.
Recruiting
Exercise in Metastatic Breast Cancer: EMBody
NA New Haven, Connecticut +4 sites NCT05468034
This trial is looking for people with metastatic breast cancer who have not seen their disease worsen in the last year. Participants will take part in a 16-week exercise program that includes aerobic and strength training.
Recruiting
Circulating Tumor DNA
PHASE2 New Haven, Connecticut +4 sites NCT06923527
This trial is looking for women with ER+ breast cancer who have tested positive for circulating tumor DNA. Participants will receive a treatment called elacestrant and will go through three phases: screening, treatment, and follow-up.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
PHASE3 New Haven, Connecticut +4 sites NCT06507618
Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
PHASE1 Springdale, Arkansas +4 sites NCT06638307
This trial is looking for adults with advanced breast cancer that cannot be cured. Participants will take a new treatment called MEN2312 to see how it works in this situation.
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3 Birmingham, Alabama +4 sites NCT04852887
This trial is looking for women with early-stage hormone-sensitive breast cancer who are interested in taking part in a study on surgery and hormone therapy without radiation. Participants will need to meet specific health criteria to join.
Recruiting
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NA New Haven, Connecticut +3 sites NCT06275126
Recruiting

Where the Breast Cancer studies are in Connecticut

  • Yale University, New Haven23 trials
  • Yale Cancer Center, New Haven18 trials
  • Smilow Cancer Hospital Care Center - Guilford, Guilford9 trials
  • Smilow Cancer Hospital Care Center - Waterford, Waterford9 trials
  • Smilow Cancer Hospital Care Center at Greenwich, Greenwich9 trials
  • Smilow Cancer Hospital Care Center at Long Ridge, Stamford9 trials

Counts are recruiting studies listing at least one site in Connecticut, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in Connecticut: common questions

How many Breast Cancer clinical trials are recruiting in Connecticut?
TrialFinder currently lists 100 recruiting Breast Cancer clinical trials with study sites in Connecticut. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in Connecticut?
Study sites for the Breast Cancer trials listed on this page include New Haven, Derby, Stamford. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Breast Cancer clinical trial in Connecticut?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in Connecticut also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in Connecticut?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in Connecticut.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →